3D-QSAR-assisted design, synthesis, and evaluation of novobiocin analogues

ACS Medicinal Chemistry Letters

Volumn 4, Issue 1, 2013, Pages 57-62

  Zhao, Huiping ^a   Moroni, Elisabetta ^b   Yan, Bin ^a   Colombo, Giorgio ^b   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b CNR   (Italy)

Author keywords

3D QSAR; breast cancer; heat shock protein 90; Hsp90 inhibitors; novobiocin

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; NOVOBIOCIN;

ARTICLE; CANCER CELL CULTURE; CHEMICAL BOND; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; IC 50; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION;

EID: 84872307764     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300275g     Document Type: Article

References (21)

1. Blagg, B. S. J.; Kerr, T. A. Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation Med. Res. Rev. 2006, 26, 310-338
2. Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90 J. Mol. Med. (Heidelberg, Germany) 2004, 82, 488-499
3. Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation Cell 2011, 144, 646-674
4. Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W. C. Heat Shock Protein 90: Inhibitors in Clinical Trials J. Med. Chem. 2010, 53, 3-17
5. Zhao, H. P.; Michaelis, M. L.; Blagg, B. S. J. Hsp90 modulation for the treatment of Alzheimer's disease Adv. Pharmacol. 2012, 64, 1-25
6. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone J. Biol. Chem. 2000, 275, 37181-37186
7. Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J. Hsp90 inhibitors identified from a library of novobiocin analogues J. Am. Chem. Soc. 2005, 127, 12778-12779
8. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90 J. Am. Chem. Soc. 2006, 128, 15529-15536
9. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines J. Org. Chem. 2008, 73, 2130-2137
10. Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity J. Org. Chem. 2008, 73, 8901-8920
11. Zhao, H. P.; Kusuma, B. R.; Blagg, B. S. J. Synthesis and evaluation of noviose replacements on novobiocin that manifest antiproliferative activity ACS Med. Chem. Lett. 2010, 1, 311-315
12. Donnelly, A. C.; Zhao, H. P.; Kusuma, B. R.; Blagg, B. S. J. Cytotoxic sugar analogues of an optimized novobiocin scaffold MedChemComm 2010, 1, 165-170
13. Zhao, H. P.; Donnelly, A. C.; Kusuma, B. R.; Brandt, G. E. L.; Brown, D.; Rajewski, R. A.; Vielhauer, G.; Holzbeierlein, J.; Cohen, M. S.; Blagg, B. S. J. Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-proliferative Agents J. Med. Chem. 2011, 54, 3839-3853
14. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S. GRid-INdependent Descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors J. Med. Chem. 2000, 43, 3233-3243
15. Duran, A.; Martinez, G. C.; Pastor, M. Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in molecular interaction fields J. Chem. Inf. Model. 2008, 48, 1813-1823
16. Duran, A.; Zamora, I.; Pastor, M. Suitability of GRIND-based principal properties for the description of molecular similarity and ligand-based virtual screening J. Chem. Inf. Model. 2009, 49, 2129-2138
17. Fontaine, F.; Pastor, M.; Sanz, F. Incorporating molecular shape into the alignment free GRid-INdependent descriptors J. Med. Chem. 2004, 47, 2805-2815
18. Goodford, P. J. Computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857
19. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems Quant. Struct.-Act. Relat. 1993, 12, 9-20
20. Zhao, H. P.; Brandt, G. E.; Galam, L.; Matts, R. L.; Blagg, B. S. J. Identification and initial SAR of silybin: An Hsp90 inhibitor Bioorg. Med. Chem. Lett. 2011, 21, 2659-2664
21. Zhao, H. P.; Yan, B.; Peterson, L. B.; Blagg, B. S. J. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition ACS Med. Chem. Lett. 2012, 3, 327-331